Cargando…

Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges

SIMPLE SUMMARY: Minimal residual disease (MRD) describes the detection of a few remaining malignant cells in blood or bone marrow with molecular methods or flow cytometry. The detection of MRD in patients with leukemia during therapy indicates the risk of relapse. Its use for treatment stratificatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mussolin, Lara, Damm-Welk, Christine, Pillon, Marta, Woessmann, Wilhelm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071445/ https://www.ncbi.nlm.nih.gov/pubmed/33921029 http://dx.doi.org/10.3390/cancers13081907

Ejemplares similares

Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?
por: Damm-Welk, Christine, et al.
Publicado: (2022)

Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2018)

Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemia
por: Möker, Paula, et al.
Publicado: (2022)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Quantitative Plasma Proteomics to Identify Candidate Biomarkers of Relapse in Pediatric/Adolescent Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2022)

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
por: Damm-Welk, Christine, et al.
Publicado: (2020)

HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma
por: De Re, Valli, et al.
Publicado: (2017)

Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma
por: Primerano, Simona, et al.
Publicado: (2016)

Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence
por: Repetto, Ombretta, et al.
Publicado: (2021)

Extranodal Biphenotypic Non-Hodgkin Lymphoma of the Popliteal Cavity: A Case Report and Review of Literature
por: Restivo, Giulia A., et al.
Publicado: (2022)

Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma
por: Krumbholz, Manuela, et al.
Publicado: (2018)

[(18)F]FDG PET-MR in the Evaluation and Follow-Up of Incidental Bone Ischemic Lesions in a Mono-Center Cohort of Pediatric Patients Affected by Hodgkin’s Lymphoma
por: Giraudo, Chiara, et al.
Publicado: (2023)

Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma
por: De Re, Valli, et al.
Publicado: (2022)

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial
por: Mussolin, Lara, et al.
Publicado: (2020)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2020)

Plasma Cell-Free DNA in Paediatric Lymphomas
por: Mussolin, Lara, et al.
Publicado: (2013)

Advances in the treatment of Hodgkin lymphoma: Current and future approaches
por: Ullah, Fauzia, et al.
Publicado: (2023)

Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas
por: Cerchietti, Leandro, et al.
Publicado: (2011)

RNY4 in Circulating Exosomes of Patients With Pediatric Anaplastic Large Cell Lymphoma: An Active Player?
por: Lovisa, Federica, et al.
Publicado: (2020)

Prospective Evaluation of Different Methods for Volumetric Analysis on [(18)F]FDG PET/CT in Pediatric Hodgkin Lymphoma
por: Lopci, Egesta, et al.
Publicado: (2022)

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future
por: Sorge, Caryn E., et al.
Publicado: (2016)

Proteomic Identification of Plasma Biomarkers in Children and Adolescents with Recurrent Hodgkin Lymphoma
por: Repetto, Ombretta, et al.
Publicado: (2018)

Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma
por: Pomari, Elena, et al.
Publicado: (2017)

Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary?
por: Farruggia, Piero, et al.
Publicado: (2016)

Current advances in Hodgkin’s lymphoma
por: Vadakara, Joseph, et al.
Publicado: (2019)

Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia
por: Veltri, Giulia, et al.
Publicado: (2022)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

miR-939 acts as tumor suppressor by modulating JUNB transcriptional activity in pediatric anaplastic large cell lymphoma
por: Garbin, Anna, et al.
Publicado: (2020)

Are Semiquantitative Methods Superior to Deauville Scoring in the Monitoring Therapy Response for Pediatric Hodgkin Lymphoma?
por: Ibrahim, Firuz, et al.
Publicado: (2023)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
por: Momotow, Jesko, et al.
Publicado: (2021)

Dose-adjusted EPOCH-rituximab or intensified B-non-Hodgkin lymphoma therapy for pediatric primary mediastinal large B-cell lymphoma. Results from the study B-NHL-BFM-04 and the NHL-BFM registry 2012
por: Knörr, Fabian, et al.
Publicado: (2021)

AuNP Aptasensor for Hodgkin Lymphoma Monitoring
por: Slyusarenko, Maria, et al.
Publicado: (2022)

Current approaches to the treatment of non-Hodgkin's lymphoma
por: Gisselbrecht, Christian
Publicado: (2011)

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
por: Pytlik, Robert, et al.
Publicado: (2020)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

(90)Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin’s lymphoma: current status and future prospects
por: Jacobs, Samuel A
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_gilmaeg39l6ug3loubvil9kl02